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RESPONSE:  TIPSTERS WEIGH IN: PUTTING GOOD SCIENCE TO WORK
Felipe Castro, M.S.W., Ph.D.; Richard A. Rawson, Ph.D.; and Ewa Stamper, Ph.D.
Richard A. Rawson chaired and Felipe Castro
and Ewa Stamper served on the 15-member
consensus panel that created SAMHSA’s TIP
33: Treatment for Stimulant Use Disorders.
Richard A. Rawson: The paper struck me
first of all as a valuable personal account
of a treatment program achieving positive
outcomes with methamphetamine abusers.
There has been a pervasive, unsubstantiated
rumor that meth abusers do not respond to
treatment. Recent studies (e.g., Hser, Evans,
and Huang, 2005; Rawson et al., 2004; Roll
et al., 2006) have begun to dispel that myth
and prove that community treatment can
produce results. The Prairie Ridge experi-
ence provides a clear instance of that. 
I am pleased that Mr. Hansen felt that
the TIP enhanced the tools and strategies
they were using, and that it got a positive
response from the staff. 
Ewa Stamper: In my opinion, the program
used the TIP extremely appropriately. They
understood the most important thing, which
was the client-centered, nonrigid approach.
They also adopted the TIP’s way of looking
at relapse as a normal phenomenon in early
recovery rather than treatment failure,
and the need for a rest period before start-
ing treatment. They got the key concepts;
the details aren’t so important.
Felipe Castro: Prairie Ridge seems to have
done a good job of taking good science and
modifying it as necessary to make it work
in their circumstances. Unfortunately, other
programs sometimes change things they
don’t like, take things out that aren’t con-
venient, and end up with a watered-down
rendition of the treatment that is unlikely
to be effective. I call that mis-adaptation, as
opposed to adaptation.
Rawson: We didn’t intend the document
to be a treatment manual. Our idea was to
introduce ideas and concepts and allow cli-
nicians to employ those they found use-
ful. In that light, Mr. Hansen’s struggles
to apply TIP 33 with mixed groups of 
patients, not all of whom abused meth, were
very instructive to read about. While there
is good agreement that the patient-centered
approach applies to all drug treatments,
there have not been a lot of comparative
studies on whether a particular set of pro-
tocols that was designed to treat one set of
patients can also be used successfully with
another. Without those data, I think cli-
nicians logically should determine for them-
selves which strategies to apply widely and
which only narrowly.
Castro: It is inevitable that clinical judg-
ment will come into play in these situations,
but it is important that these decisions aren’t
made haphazardly. Ideally, we should be
able to teach clinicians how to make adap-
tations based on their local situation with-
out removing the treatment from the 
context of the original, evidence-based
approach.
Stamper: I was especially impressed by the
spirit of continuing education and open-
ness to new ideas among the staff at Prairie
Ridge. Unfortunately, I don’t think that’s
typical of rural or smaller centers. At least
here in Hawaii, treatment providers some-
times tend to distance themselves from the
research community and to be entrenched
in what they know and what works for them. 
Neurobiological and gender issues
Rawson:  I found it very encouraging that
the author made use of the information on
the neurobiological effects of the drug on
the brain. For many treatment programs,
the idea that neurobiology is relevant to
treatment and recovery is revolutionary. I
also was gratified that Prairie Ridge utilized
the information on the sexual effects of meth
abuse. I think that is an understudied area,
despite its obvious importance to drug abuse
treatment.  
Stamper: The author’s remark that there is
inevitable discomfort when counselors talk
about sexual issues made me sad, though it’s
understandable. It will be best for everyone
if this discomfort is eliminated. Frankly, the
more counselors are prepared and knowl-
edgeable and practiced in talking about these
issues, the less discomfort there is for both
parties.
Castro: Most drugs cause sexual problems,
either fueling or suppressing sexual drive.
These problems may be more pronounced
with stimulants than with other drugs.
I’ve been conducting research in a com-
munity residential program where we see
only men. Almost all our patients have
sexual problems and also problems with their
families, where their role as protector and
provider has been damaged by their drug
abuse. The program addresses sexual issues
as an important part of these broader gen-
der and relationship issues that must be faced
in treatment. In many cases, addressing sex
and gender issues is a necessary step in help-
ing patients return to society and their fam-
ilies, where there is a need to reconnect after
the relationship has been damaged. 
Stamper: Sex means different things for dif-
ferent genders. For female users, sexual issues
are very often intertwined with issues of
trauma, sexual abuse, and violence. They
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(the dealer “boyfriend”), as well as prosti-
tution. These things do tie together and they
need to be addressed more and more.
Evaluation: Always recommended,
always possible
Castro: I was disappointed that the author
believed they couldn’t evaluate their inno-
vations because they were unable to imple-
ment the TIP with absolute fidelity. I think
we can always evaluate, albeit with varying
degrees of precision. All programs should
be committed to some level of monitor-
ing so that corrections can be made during
the treatment process. Even asking a very
simple set of questions in an exit interview,
such as, “How much did the client like
the information?” or “How effective did the
client find it on a scale from 1 to 5?” can
give a broad, but useful, idea of the efficacy
of treatment.
Rawson: Consumer and staff satisfaction
surveys are useful and relatively straight-
forward to do. In our program, when we
implement new strategies and treatments,
we monitor whether or not they improve
retention. That is useful because people who
stay in treatment longer do better. Drug
screens can be used in a similar manner. A
program can look at the 50 patients they
treated before the change was implemented
and the first 50 patients after and com-
pare the results of their urine screens.
Stamper: I especially like the retention
measure. It is certainly doable, and it’s also
immediately practical, through its con-
nection to reimbursement. However, we
do need to acknowledge that even the sim-
plest measures require at least some invest-
our methods of dissemination. The TIP has
not had much of an impact in my com-
munity.
Rawson: We’ve received very little feedback
about the TIP. I have heard from programs
in Iowa, which has mandated its use as a
guide for treating methamphetamine abuse.
The reports have been mixed. Some peo-
ple, like Mr. Hansen, appear to have pro-
grams where people are open to new ideas.
Other places have told me, “We don’t see
anything new about this. It’s what we’ve
always done.” That’s a response I’ve been
hearing for 30 years from people who base
their treatment approach on their personal
values and beliefs and don’t want to be con-
fused with information. Luckily, there is
increasing awareness of the term “evidence-
based practices” and the need to do things
differently.
Stamper: Researchers and technology trans-
fer groups need to find ways to disseminate
science-based practices that fit counselors’
cognitive styles. Among the Hawaiians in
my community, and I imagine some other
ethnic groups, the oral tradition is very
strong. They will welcome face-to-face pres-
entations with in-depth learning opportu-
nities, but probably won’t pick up a thick
book. Counselors with less formal educa-
tion tend to think very concretely. For them,
a less conceptual, more cookbook-like pres-
entation might work better. You don’t need
to have a broad conceptual framework to
assimilate information creatively. &
ment of time and money. Everybody in a
treatment program is overworked and usu-
ally no special funds are available for some-
one to sit and crunch these numbers. So
the reality of the situation is: the simpler,
the better.
Next steps
Stamper: I have been advocating for a revi-
sion to TIP 33 for several years. We know
much more today than we did when we were
writing it. A revision could incorporate new
knowledge on issues such as special popu-
lations and neurobiology, as well as new 
evidence from clinical trials. I would also
like to see an acknowledgment in the TIP
that the majority of patients in treatment
centers abuse multiple drugs. We could
advise clinicians such as Mr. Hansen on how
to deal with this issue, which he rightly
treated as a major concern.
Castro: NIDA’s big developments in neu-
roimaging research should be included in a
revision.
Rawson: I would second that idea. The brain
imaging work has taught us a lot about how
some areas of the brain that meth impacts
recover with abstinence, how that influences
people’s behavior during recovery, and what
kinds of treatment techniques can be use-
ful. We also now have a significant amount
of clinical treatment outcome literature on
both cocaine and methamphetamine, so
there is a wealth of new information we
could use to expand treatment recommen-
dations (Rawson, Gonzales, and Ling, 2006).  
Stamper: In addition to updating the TIP,
I would suggest that we try to improve
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